Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140248 | 0.78 | SMN1; SMN2 (0.46) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL13247791 | 0.77 | L3MBTL1 (0.45) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL12188234 | 0.75 | L3MBTL1 (0.46) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL2733187 | 0.75 | LMNA (0.56) | SMN1; SMN2RAB9AHTTL3MBTL1MAPK1 | |
| SCHEMBL823599 | 0.74 | NPSR1 (0.41) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL2731993 | 0.71 | NPC1 (0.45) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL15945546 | 0.69 | NPC1 (0.45) | NPC1SMN1; SMN2RAB9AHTTCNR1 | |
| SCHEMBL8738333 | 0.69 | PIK3CG (0.36) | NPC1SMN1; SMN2RAB9AHTTALDH1A1 | |
| SCHEMBL24264721 | 0.69 | KMT2A (0.48) | NPC1SMN1; SMN2RAB9AHTTL3MBTL1 | |
| SCHEMBL21889211 | 0.68 | SMN1; SMN2 (0.34) | NPC1SMN1; SMN2RAB9AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | NPC1 742/4885SMN1; SMN2 1064/4885RAB9A 2559/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | NPC1 742/4885SMN1; SMN2 1064/4885RAB9A 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.